PURPOSE: To evaluate the practicability of en bloc transurethral resection with 2-micron continuous-wave laser as treatment for primary non-muscle-invasive bladder cancer (NMIBC). METHODS: This was a single-center, randomized, controlled trial involving 142 patients with newly diagnosed NMIBC. All patients were randomly assigned in a 1:1 ratio to receive either laser treatment or conventional transurethral resection of bladder tumor (TURBT). All patients received intravesical chemotherapy. Follow-up was performed in 18 months. Primary outcome measure was difference of tumor recurrence rate at the end of study. RESULTS: Baseline characteristics did not differ between patients in two groups. Operation time was longer in laser group than in TURBT group (56.5 ± 37.4 vs. 41.0 ± 29.4 min, P = 0.017). Obturator nerve reflection was noted during TURBT in 18 patients, whereas none was noted during laser resection. Number of T1 tumors was higher in the laser group (25 vs. 15, P = 0.047). According to Kaplan-Meier survival curves, there was no statistical difference in the rate of recurrence in 18 months (P = 0.383). All recurrences were out of the site of first resection, and there was no progression in tumor grade. CONCLUSION: Two-micron continuous-wave laser did not diminish tumor recurrence rate in primary NMIBC for 18-months observation. However, T1 tumors were significantly higher among laser group. Clear and complete tumor bases were easily conserved by laser resection, which may enable pathologists to distinguish the T stages of bladder cancer more easily. Further studies need to be done in future.
RCT Entities:
PURPOSE: To evaluate the practicability of en bloc transurethral resection with 2-micron continuous-wave laser as treatment for primary non-muscle-invasive bladder cancer (NMIBC). METHODS: This was a single-center, randomized, controlled trial involving 142 patients with newly diagnosed NMIBC. All patients were randomly assigned in a 1:1 ratio to receive either laser treatment or conventional transurethral resection of bladder tumor (TURBT). All patients received intravesical chemotherapy. Follow-up was performed in 18 months. Primary outcome measure was difference of tumor recurrence rate at the end of study. RESULTS: Baseline characteristics did not differ between patients in two groups. Operation time was longer in laser group than in TURBT group (56.5 ± 37.4 vs. 41.0 ± 29.4 min, P = 0.017). Obturator nerve reflection was noted during TURBT in 18 patients, whereas none was noted during laser resection. Number of T1 tumors was higher in the laser group (25 vs. 15, P = 0.047). According to Kaplan-Meier survival curves, there was no statistical difference in the rate of recurrence in 18 months (P = 0.383). All recurrences were out of the site of first resection, and there was no progression in tumor grade. CONCLUSION: Two-micron continuous-wave laser did not diminish tumor recurrence rate in primary NMIBC for 18-months observation. However, T1 tumors were significantly higher among laser group. Clear and complete tumor bases were easily conserved by laser resection, which may enable pathologists to distinguish the T stages of bladder cancer more easily. Further studies need to be done in future.
Authors: Marco G Bol; Jan P Baak; Susanne Buhr-Wildhagen; Arnold-Jan Kruse; Kjell H Kjellevold; Emiel A Janssen; Oddvar Mestad; Per Øgreid Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Thomas R W Herrmann; Evangelos N Liatsikos; Udo Nagele; Olivier Traxer; Axel S Merseburger Journal: Eur Urol Date: 2012-01-17 Impact factor: 20.096
Authors: Morgan Rouprêt; Thomas Seisen; Eva Compérat; Stéphane Larré; Catherine Mazerolles; Françoise Gobet; Franck Fetissof; Gaelle Fromont; Athmane Safsaf; Benjamin Faivre d'Arcier; Olivier Celhay; Pierre Validire; François Rozet; Jacques Irani; Michel Soulié; Christian Pfister Journal: J Urol Date: 2012-11-28 Impact factor: 7.450
Authors: Markus J Bader; Ronald Sroka; Christian Gratzke; Michael Seitz; Patrick Weidlich; Michael Staehler; Armin Becker; Christian G Stief; Oliver Reich Journal: Eur Urol Date: 2008-12-17 Impact factor: 20.096